Biotechnology and Bioprocess Engineering

, Volume 16, Issue 3, pp 617–623 | Cite as

Paromomycin loaded solid lipid nanoparticles: Characterization of production parameters

  • Maryam Ghadiri
  • Alireza Vatanara
  • Delaram Doroud
  • A. Roholamini Najafabadi
Research Paper
First Online:
Received:
Revised:
Accepted:

Abstract

Paromomycin has been shown to have anti-leishmaniasis activity; however, its clinical use is restricted to some content owing to its poor skin penetration. To identify innovative methods of dermal administration of paromomycin and controlling the release delivery system, paromomycin was loaded into the solid lipid media as nanoparticles. Type of the method; microemulsion or solvent diffusion, the type of lipid; cetyl palmitate or stearic acid, were comparatively investigated on the average diameter, size distribution and entrapment efficiency of the lipid nanoparticles to maximize entrapment efficiency, reduce the particle size and its distribution. Three quantitative factors, paromomycin content, weight fraction of Tween 80 and drug to lipid ratio, were also investigated at two levels for Solid Lipid Nanoparticles (SLNs) formulation in a fractional factorial design. The results indicated that microemulsion was the most efficient method and stearic acid was the preferred lipid for SLNs formulation. The average size of the particles was reduced to 299.08 nm and the entrapment efficiency was enhanced from immediate release to 24 h.

Keywords

lipid nanoparticles paromomycin drug delivery 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Desjeux, P. (1992) Human leishmaniases: Epidemiology and public health aspects. World Health Stat. Q. 45: 267–75.Google Scholar
  2. 2.
    Richens, J. (2004) Genital manifestations of tropical diseases. Sex Transm. Infect. 80: 12–17.CrossRefGoogle Scholar
  3. 3.
    Bryceson ADM. (1987) Therapy in man. In: Peters W, Killick-Kendrick R editor. The Leishmaniasis in Biology and Medicine. volume 2: London: Academic Press; p. 847–907.Google Scholar
  4. 4.
    Garnier, T. and S. L. Croft (2002) Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs 3: 538–544.Google Scholar
  5. 5.
    Asilian, A., A. Sadeghinia, G. Faghihi, A. Momeni, and A. Amini Harandi (2003) The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann. Trop Med. Parasitol. 97: 493–498.CrossRefGoogle Scholar
  6. 6.
    Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, and S. L. Croft (2002) Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2: 494–501.CrossRefGoogle Scholar
  7. 7.
    Tulkens, P. M. (1991) Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10: 100–106.CrossRefGoogle Scholar
  8. 8.
    Armijos, R. X., M. M. Weigel, M. Calvopina, M. Mancheno, and R. Rodriguez (2004) Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91: 153–160.CrossRefGoogle Scholar
  9. 9.
    Ferreira, L. S., G. A. Ramaldes, E. A. Nunan, and L. A. M. Ferreira (2004) In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev. Ind. Pharm. 30: 289–296.CrossRefGoogle Scholar
  10. 10.
    Mauel, J. (1990) Macrophage parasite interactions in Leishmania infections. J. Leukoc. Biol. 47: 187–193.Google Scholar
  11. 11.
    Food Drug Cosmetic Law Reports, (1994) Commerce Clearing House Inc. Google Scholar
  12. 12.
    Mehnert, W. and K. Mader (2001) Solid lipid nanoparticles production characterization and applications. Adv. Drug Deliv. Rev. 47: 165–196.CrossRefGoogle Scholar
  13. 13.
    Liu, J., W. Hu, H. Chen, Q. Ni, H. Xu, and X. Yang (2007) Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 328: 191–195.CrossRefGoogle Scholar
  14. 14.
    Mei, Z., H. Chen, T. Wang, Y. Yang, and X. Yang (2003) Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm. 56: 189–196.CrossRefGoogle Scholar
  15. 15.
    Li, Y., L. Dong, A. Jia, X. Chang, and H. Xue (2006) Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. Int. J. Biol. Macromol. 38: 296–299.CrossRefGoogle Scholar
  16. 16.
    Montgomery, D. C. (1991) Design and analysis of experiments. 3rd ed. John Wiley & Sons, NY.Google Scholar
  17. 17.
    Pick, J., L. Olson, W. Ellis, and P. Lim (1997) Development and validation of a method to extract and quantitate paromomycin and gentamicin from an Aquaphilic cream formulation. J. Pharm. Biomed. Anal. 16: 131–137.CrossRefGoogle Scholar
  18. 18.
    Lv, Q., A. Yu, Y. Xi, H. Li, Z. Song, J. Cui, F. Cao, and G. Zhai (2009) Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int. J. Pharm. 372: 191–198.CrossRefGoogle Scholar
  19. 19.
    Attama, A. A. and C. C. Muller-Goymann (2008) Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity. Colloids Surf. A: Physicochem. Eng. Asp. 315: 189–195.CrossRefGoogle Scholar
  20. 20.
    You, J., F. Wan, F. Cui, Y. Sun, Y. Du, and F. Hu (2007) Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int. J. Pharm. 343: 270–276.CrossRefGoogle Scholar
  21. 21.
    You, J., F. Wan, Y. Sun, X. Zhang, F. Cui, Y. Du, H. Yuan, and F. Hu (2008) Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. Int. J. Pharma. 359: 104–110.CrossRefGoogle Scholar
  22. 22.
    Triplett, M. D. and J. F. Rathman (2009) Optimization of b-car otene loaded solid lipid nanoparticles preparation using a high shear homogenization technique. J. Nanopart. Res. 11: 601–614.CrossRefGoogle Scholar
  23. 23.
    Yuan, H., L. F. Huang, Y. Z. Du, X. Y. Ying, J. You, F. Q. Hu, and S. Zeng (2007) Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system. Colloids and Surfaces B: Biointerfaces 61: 132–137.CrossRefGoogle Scholar
  24. 24.
    Arcamone, M. and V. Guiseppe Cassinelli (1977) Paromomycin derivatives and process for the preparation thereof. US patent 4,021,601.Google Scholar
  25. 25.
    Wahlig, H., E. Dingeldein, and R. Kirchlechner (1986) Flavonoid phosphate salts of aminoglycoside antibiotics. US patent 4,617,293.Google Scholar

Copyright information

© The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Maryam Ghadiri
    • 1
  • Alireza Vatanara
    • 2
  • Delaram Doroud
    • 1
  • A. Roholamini Najafabadi
    • 2
  1. 1.Department of Chemical Engineering, Faculty of EngineeringUniversity of TehranTehranIran
  2. 2.Department of Pharmaceutics, School of PharmacyTehran University of Medical SciencesTehranIran

Personalised recommendations